公开(公告)号：US20240350455A1

公开(公告)日：2024-10-24

申请号：US18629089

申请日：2024-04-08

申请人： CAAMTECH, INC.

发明人： Andrew R. CHADEAYNE

IPC分类号： A61K31/4045 ,  A61K31/36 ,  A61K31/48

CPC分类号： A61K31/4045 ,  A61K31/36 ,  A61K31/48

摘要： This disclosure pertains to new compositions and methods comprising a first serotonergic drug and a second serotonergic drug. In one embodiment, the compositions disclosed herein are used for a method of regulating a neurotransmitter receptor, e.g., a serotonin receptor. In one embodiment, the compositions disclosed herein comprise purified compounds, e.g., a purified psilocybin derivative, a purified cannabinoid, a purified terpene, a purified tryptamine, purified LSD, and/or purified MDMA.

公开(公告)号：US20240325378A1

公开(公告)日：2024-10-03

申请号：US18622144

申请日：2024-03-29

申请人： University of Oregon

发明人： Balamurali Ambati ,  Sangeetha Ravi Kumar ,  Kieley Trempy ,  Xiaohui Zhang

IPC分类号： A61K31/48 ,  A61K9/00 ,  A61K9/08 ,  A61P27/02

CPC分类号： A61K31/48 ,  A61K9/0048 ,  A61K9/08 ,  A61P27/02

摘要： Chemical injuries to the eye can cause permanent vision impairment or blindness, as well as chronic pain and dry eye syndrome. Disclosed herein is a method of treating an ocular chemical burn by administering an effective amount of pergolide to an eye of a subject, such as via a topical formulation. Further disclosed are compositions and kits used for that treatment, such as pergolide solutions, and pergolide eye drop formulations.

公开(公告)号：US12083116B2

公开(公告)日：2024-09-10

申请号：US17254534

申请日：2019-06-21

申请人： Robert John Petcavich

发明人： Robert John Petcavich

IPC分类号： A61K31/48 ,  A61K9/00 ,  A61K9/70 ,  A61K31/05 ,  A61K31/12 ,  A61K31/137 ,  A61K31/15 ,  A61K31/155 ,  A61K31/352 ,  A61K31/353 ,  A61K31/355 ,  A61K31/36 ,  A61K31/375 ,  A61K31/4045 ,  A61K31/426 ,  A61K31/675 ,  A61K31/706 ,  A61K45/06 ,  A61P25/28

CPC分类号： A61K31/48 ,  A61K9/006 ,  A61K9/7007 ,  A61K31/05 ,  A61K31/12 ,  A61K31/137 ,  A61K31/15 ,  A61K31/155 ,  A61K31/352 ,  A61K31/353 ,  A61K31/355 ,  A61K31/36 ,  A61K31/375 ,  A61K31/4045 ,  A61K31/426 ,  A61K31/675 ,  A61K31/706 ,  A61K45/06 ,  A61P25/28

摘要： The present invention discloses a method to recover and restore dendritic and synaptic neuron connections that have been degraded or destroyed by neurodegenerative diseases. In the present invention tryptamines are used to induce neuro plasticity and restore both dendritic density and synaptic connections of neurons in the brain. In the preferred embodiment LSD given in micro doses can induce dendritic and synaptic genesis in neuronal networks and improve the quality of life of people with neurodegenerative diseases such as Alzheimer's, Huntington's, Multiple Sclerosis, Parkinson's and Frontotemporal dementia.

公开(公告)号：US20240287057A1

公开(公告)日：2024-08-29

申请号：US18400508

申请日：2023-12-29

申请人： Ceruvia Lifesciences LLC

发明人： Annalisa Mortoni ,  Eugenio Castelli ,  John M. Wetzel

IPC分类号： C07D457/06 ,  A61K31/48

CPC分类号： C07D457/06 ,  A61K31/48

摘要： Disclosed herein, inter alia, are a process for the preparation of 2-bromolysergic acid diethylamide (2-Br-LSD), or a pharmaceutically acceptable salt thereof, via the controlled hydrolysis of bromocriptine to form 2-bromolysergic acid, followed by amidation to form 2-Br-LSD, the purified 2-Br-LSD, per se, and pharmaceutical compositions containing the purified 2-Br-LSD, per se, and uses thereof.

公开(公告)号：US12018402B2

公开(公告)日：2024-06-25

申请号：US16325856

申请日：2017-08-17

申请人： Quest Diagnostics Investments LLC

发明人： Michael J. McPhaul ,  Heather R. Sanders

IPC分类号： C40B30/04 ,  A61K31/03 ,  A61K31/48 ,  A61K31/567 ,  A61K31/4174 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/451 ,  A61K31/496 ,  A61K31/506 ,  C12Q1/6806 ,  C12Q1/6886

CPC分类号： C40B30/04 ,  A61K31/03 ,  A61K31/48 ,  A61K31/567 ,  A61K31/4174 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/451 ,  A61K31/496 ,  A61K31/506 ,  C12Q1/6806 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/156

摘要： The present technology is related to methods for detecting genetic alterations underlying intracranial neoplasms such as pituitary adenomas, meningiomas, and craniopharyngiomas. The methods disclosed herein are useful in determining whether a patient harboring an intracranial tumor will benefit from or is predicted to be responsive to treatment with an individual therapeutic agent or a specific combination of therapeutic agents. Kits for use in practicing the methods are also provided.

公开(公告)号：US20240115564A1

公开(公告)日：2024-04-11

申请号：US18271588

申请日：2022-01-11

申请人： The Regents of the University of California

发明人： Gregory Ku

IPC分类号： A61K31/496 ,  A61K31/4709 ,  A61K31/48 ,  A61K31/7088 ,  A61P3/10

CPC分类号： A61K31/496 ,  A61K31/4709 ,  A61K31/48 ,  A61K31/7088 ,  A61P3/10 ,  A61K2039/505

摘要： Methods for treating diabetes are described. The methods include administration of a serotonin receptor 1F (HTR1F) antagonist, such as a substituted piperidine, methysergide, or methiothepin, to a subject in need thereof. Administration of the HTR1F antagonist can increase survival of pancreatic beta cells in conjunction with pancreatic islet transplantation. Methods for transplanting pancreatic islets to subjects such as diabetes patients are also described.

公开(公告)号：US20240108619A1

公开(公告)日：2024-04-04

申请号：US18479335

申请日：2023-10-02

申请人： Satsuma Pharmaceuticals, Inc.

发明人： Shunji Haruta ,  Nikhilesh N. Singh ,  John Kollins ,  Salvador Rico

IPC分类号： A61K31/4985 ,  A61K9/00 ,  A61K9/14 ,  A61K31/48 ,  A61K31/522 ,  A61K45/06 ,  A61K47/02 ,  A61K47/22 ,  A61K47/38

CPC分类号： A61K31/4985 ,  A61K9/0043 ,  A61K9/146 ,  A61K31/48 ,  A61K31/522 ,  A61K45/06 ,  A61K47/02 ,  A61K47/22 ,  A61K47/38

摘要： Presented herein are powder formulations comprising dihydroergotamine (DHE), or a pharmaceutically acceptable salt thereof. In addition to such formulations, also presented herein are methods comprising intranasally administering powder formulations comprising dihydroergotamine, or a pharmaceutically acceptable salt thereof. The presented methods can be used for treating headache, for example, for rapid onset treatment of headache, including migraine, e.g. acute treatment of migraine with or without aura.

公开(公告)号：US11872314B2

公开(公告)日：2024-01-16

申请号：US17005647

申请日：2020-08-28

申请人： Shin Nippon Biomedical Laboratories, Ltd.

发明人： Shunji Haruta

IPC分类号： A61K9/14 ,  A61K9/16 ,  A61K31/517 ,  A61K31/48 ,  A61K31/515 ,  A61K9/00 ,  A61K9/19 ,  A61K31/405 ,  A61K31/4985 ,  A61K31/568

CPC分类号： A61K9/1652 ,  A61K9/0043 ,  A61K9/146 ,  A61K9/1623 ,  A61K9/1694 ,  A61K9/19 ,  A61K31/405 ,  A61K31/48 ,  A61K31/4985 ,  A61K31/515 ,  A61K31/517 ,  A61K31/568 ,  C07B2200/13

摘要： Disclosed herein are pharmaceutical powder compositions, methods of making such compositions, and uses thereof.

公开(公告)号：US20230372295A1

公开(公告)日：2023-11-23

申请号：US18229286

申请日：2023-08-02

申请人： Psilera Inc.

发明人： Christopher G. Witowski ,  Jacqueline L. Salm

IPC分类号： A61K31/4045 ,  A61K9/20 ,  A61K31/48 ,  A61K31/675 ,  A61K31/55 ,  A61K31/405 ,  A61K9/00 ,  A61K9/70 ,  A61K9/06 ,  C07D209/16

CPC分类号： A61K31/4045 ,  A61K9/2013 ,  A61K31/48 ,  A61K31/675 ,  A61K31/55 ,  A61K31/405 ,  A61K9/0043 ,  A61K9/7061 ,  A61K9/06 ,  A61K9/7069 ,  A61K9/2054 ,  A61K9/2009 ,  A61K9/2018 ,  A61K9/2027 ,  C07D209/16

摘要： Pharmaceutical formulations of novel indole compounds and psilocybin analogs are manufactured, provided in novel oral, transdermal, and nasal pharmaceutical compositions for use to treat neurological, mood or abuse diseases and disorders.

公开(公告)号：US20230293443A1

公开(公告)日：2023-09-21

申请号：US18121626

申请日：2023-03-15

申请人： Duke University

发明人： Tong Hyon LEE

IPC分类号： A61K9/48 ,  A61K9/20 ,  A61K48/00 ,  A61K45/06 ,  A61K31/48 ,  A61K31/517 ,  A61P25/30 ,  A61K31/4178

CPC分类号： A61K9/48 ,  A61K9/20 ,  A61K48/00 ,  A61K45/06 ,  A61K31/48 ,  A61K31/517 ,  A61P25/30 ,  A61K31/4178 ,  A61P25/22

摘要： The present invention relates to a composition and method for combinative therapy, capable of temporarily regulating inherent dysfunctional neural processes and reducing symptoms and/or signs of neuropsychiatric disorders including, but not limited to, psychostimulant use disorder (PUD) and other substance-related additive disorders, post-traumatic stress disorder (PTSD) and other trauma- and stress-related disorders, and levodopa-induced dyskinesia (LID) and other types of dyskinesias. The present specification shows specific examples of a dosage form.